ReViral reviral.co.uk


Public list: BIO 2016 (619) Pharma Startups (4733)

ReViral is an antiviral drug discovery and development company, focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV).

ReViral is an antiviral drug discovery and development company, focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV).

Company (Alive / Active)

Phone:

Fax:

8 St. Thomas Street

London, SE1 9RS
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
ReViral $21M Sep 11, 2015

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related ReViral Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
OrbiMed AdvisorsVenture CapitalNew York, New York, United StatesSeries A
Andera PartnersAsset/Investment ManagementParis, FranceSeries A
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Pharmaceutical compounds Nov 12, 2012 Nov 07, 2017 Patent
Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv) Oct 06, 2015 Application